Project: Every Child for Younger Patients With Cancer

Summary

This registry will collect biospecimens and accompanying demographic, epidemiologic, therapeutic, and outcome data from all children diagnosed with cancer at participating Children's Oncology Group institutions, of which Carilion Clinic is one, independent of the patient’s enrollment on a specific therapeutic clinical trial. This is an observational study. Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal swab, saliva, cerebrospinal fluid, or urine). 

COG #APEC14B1

To be included in APEC14B1, participants must be / have

• Known or suspected neoplasm that occurs in the pediatric, adolescent, or young adult populations are eligible for enrollment as follows: All cancer cases with an ICD-O histologic behavior code of 2 (carcinoma in situ) or 3 (malignant). All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline, or malignant.
• Additionally eligible benign/borderline conditions:
  • Mesoblastic nephroma
  • Teratomas (mature and immature types)
  • Myeloproliferative diseases including transient myeloproliferative disease
  • Langerhans cell histiocytosis
  • Lymphoproliferative diseases
  • Desmoid tumors
  • Gonadal stromal cell tumors
• Participants must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.
• Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem.

To be included in APEC14B1, participants must not be / have

• None

Keywords

Cancer; Registry